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sive non-Hodgkin’s lymphoma (NHL) has been reported to
improve survival. However, optimal conditioning regimen has
yet to be determined. We have conducted a single institute
study to evaluate the safety and efﬁcacy of MCVAC regimen
followed by autologous PBSCT for high-risk NHL. Patients
and Methods: Adult patients with high-risk or relapsed DL-
BCL were eligible. MCVAC regimen consisted of ranimustine
(250 mg/m2 on day 9 and 200 mg/m2 on day 4), cytarabine
(2.0 g/m2 twice daily on days 8 to 5), etoposide (200 mg/m2
twice daily on days 8 to 5), and cyclophosphamide (50 mg/kg
on days 3 and 2) followed by unpurged PBSCT. Granulo-
cyte-colony stimulating factor were intravenously given from
day 1 until neutrophil recovery. Results: Forty patients were
enrolled and evaluable (median age; 51 years old). Disease status
at transplant was CR in 22, and non-CR in 18 patients. Median
follow-up was 33.3 months. Five-year overall survival (OS) and
progression free survival (PFS) were 61.3% and 60.9%, respec-
tively. Five-year OS was 58.1% in CR patients and 63.6% in
non-CR patients (not signiﬁcant), and 5-year PFS was 61.4% in
CR patients and 59.6% in non-CR patients (not signiﬁcant).
Within 30 days after transplant, only 1 patient (2.5%) died of
treatment-related complication (acute myocardial toxicity due
to cyclophosphamide). In 2 patients, secondary MDS/AML was
diagnosed at 20.3 and 94.7 months after transplant. Conclu-
sions: We conclude that MCVAC regimen would be an effec-
tive and tolerable non-TBI regimen in autologous PBSCT for
high-risk or relapsed DLBCL, and disease status at transplant
did not affect the survival.
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ISOPHOSPHORAMIDE MUSTARD-LYSINE (ZIO-201): A POTENTIAL
NEW ALKYLATOR FOR BONE MARROW TRANSPLANTS
Taub, M.1, Springate, J.E.1, Zaki, E.1, Stuck, R.2, Gale, R.P.3 1. State
University of New York, Buffalo, NY; 2. Cancer Medica, LLC, Bir-
mingham, AL; 3. ZIOPHARM Oncology, Charlestown, MA.
Cyclophosphamide (CPA) and ifosfamide (IFOS) are widely
used anti-cancer drugs. High-dose CPA has a special role in
bone marrow transplants but its use is associated with substan-
tial toxicities (kidney, bladder, and CNS) that mandate special
interventions like use of Na-2-mercaptoethane sulfonate
(mesna) and IV hydration. CPA and IFOS are pro-drugs which
must be metabolized before they cross-link DNA via phosphor-
amide (PM) and isophosphoramide mustards (IPM). Adverse
effects of CPA and IFOS result from the metabolites acrolein
(ACR) and chloroacetaldehyde (CCA), which is not directly
involved in DNA-cross-linking. Recently, a lysine-stabilized
form of IPM (IPM-lysine; ZIO-201) was developed. ZIO-201
directly cross-links DNA and is active against human cancer cell
lines and in mice with human cancer xenografts. To evaluate
kidney toxicity of ZIO-201, we used an in vitro primary rabbit
kidney proximal tubule (RPT) cell culture system, which retains
many of the characteristics of renal proximal tubule cells includ-
ing a polarized morphology, a Na/glucose co-transport system
and a p-aminohippurate transport system, glutathione state, and
hormone responses. We studied effects of ZIO-201, ACR, and
CAA on conﬂuent monolayers of primary rabbit kidney proxi-
mal tubule (RPT) cells at 15–100 M. Viability was determined
by neutral red dye uptake. ZIO-201 did not signiﬁcantly reduce
viability; LD50 for CAA was about 40 M with complete inhi-
bition at 75 M. These data show that ZIO-201 avoids the
kidney toxicity caused by metabolites of pro-drugs like CPA and
IFOS. Also, because there is also no inter-subject variability in
metabolism of ZIO-201 (unlike CPA and IFOS) and because
CPA/IFOS-resistant cells are sensitive to ZIO-201, ZIO-201
may be a useful substitute for CPA and/or IFOS in bone marrow
transplant conditioning regimens.
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INTRAVENOUS (i.v.) BUSULFAN (Bu) PLUS MELPHALAN (Mel) IS A
WELL-TOLERATED PREPARATIVE REGIMEN FOR STEM CELL TRANS-
PLANTATION (SCT) IN PATIENTS (pts) WITH ADVANCED LYMPHOID
MALIGNANCIES
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High dose chemotherapy and SCT is an accepted treatment option
for pts with relapsed lymphoid malignancies. However, relapse re-
mains a signiﬁcant issue for pts with advanced disease. A double
alkylating regimen of Bu and Mel has been suggested as an effective
and myeloablative pre-transplant conditioning regimen. Historically,
oral Bu was used and the combination resulted in considerable mu-
cositis and VOD. Recently, an i.v. formulation of Bu has been devel-
oped that has less pharmacokinetic variability. We are investigating
the safety and efﬁcacy of i.v. Bu-Mel in pts with lymphoid malignan-
cies undergoing auto- or allo-SCT. Patients and Methods: The
conditioning regimen consists of i.v. Bu 130 mg/m2 over 3 hours daily
for 4 days, either as a ﬁxed dose per BSA, or to target an average daily
AUC of 5000 mMol-min 12% determined by a test dose of i.v. Bu
at 32 mg/m2 given 48 hours prior to the high dose regimen. After the
4 daily Bu doses, there is a rest day, followed by 2 daily doses of Mel
at 70 mg/m2. Stem cells are infused the following day. Dilantin is
administered for seizure prophylaxis. GVHD prophylaxis consists of
tacrolimus and methotrexate for pts receiving allo-SCT. Results:
Twenty-ﬁve pts (17 M/8 F) with median age 40 years (range 19–65):
MM (n  5), NHL (n  5), HD (n  13), ALL (n  2). Median
number of prior chemotherapy regimens was 3 (range 1–8). At study
entry, 2 pts were in CR1; 23 were in relapse: refractory (n  3),
chemo-sensitive ﬁrst relapse (n 9), and beyond ﬁrst relapse (n 11).
Engraftment, GVHD, and toxicity data are shown in Table 1. Grades
I or II mucositis was the most common regimen-related toxicity. Of
note, there were no cases of VOD; reversible hyperbilirubinemia,
grade II (n 2) and grade III (n 1), was observed in 3 pts receiving
allo-SCT. All allo-SCT pts had 100% donor chimerism by day 30.
Twenty pts had i.v. Bu delivered per test dose guidance; 5 pts received
ﬁxed dose Bu at 130 mg/m2. The median daily systemic Bu exposure
was 4867 Mol-min. Conclusions: Intravenous Bu-Mel is well tol-
erated and enables prompt neutrophil and platelet engraftment. In-
dividualized PK-directed dosing of i.v. Bu is feasible, and likely con-
tributes to the low toxicity proﬁle of this regimen. Longer follow-up
is needed to assess disease control (Table 1).
Table 1. Engraftment, GVHD, and Regimen Toxicities
Auto-SCT Allo-SCT
No. Patients 18 7
Median CD34 cell
dose  106/kg
(range)
5.20 (2.49–10.48) 4.89 (2.27–13.31)
Median days to ANC
>0.5  109/L (range)
10 (9–11) 11 (9–19)
Median days to platelet
>20  109/L (range)
9 (8–30) 12 (10–19)
No. patients with
grade II–IV acute
GVHD
0 2
No. patients with
grade III toxicity
2 2
Type grade III toxicity mucositis renal failure,
hyperbilirubinemia
No. Patients with
grade IV toxicity
0 0
No. Deaths with 8
month follow-up
0 2
Cause of death disease progression,
GVHD
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